Table 1.
Patient characteristics.
| Entire cohort N = 150 |
Discovery cohort N = 105 |
Validation cohort N = 45 |
p-values* | |
|---|---|---|---|---|
| Median patient age, years (IQR) | 64 (58–71) | 65 (59–71) | 62 (56–68) | 0.10 |
| Histology, number (%) | 0.09 | |||
| Endometrioid | 62 (41.3%) | 45 (42.9%) | 17 (37.8%) | |
| Serous | 31 (20.7%) | 22 (21.0%) | 9 (20.0%) | |
| Clear cell | 11 (7.3%) | 8 (7.6%) | 3 (6.7%) | |
| Carcinosarcoma | 26 (17.3%) | 15 (14.3%) | 11 (24.4%) | |
| Undifferentiated/dedifferentiated | 6 (4.0%) | 2 (1.9%) | 4 (8.9%) | |
| Unclassified high-grade type | 14 (9.3%) | 13 (12.4%) | 1 (2.2%) | |
| Tumor grade, number (%) | 0.60 | |||
| Well/moderately differentiated | 109 (72.7%) | 75 (71.4%) | 34 (75.6%) | |
| Poorly differentiated | 41 (27.3%) | 30 (28.6%) | 11 (24.4%) | |
| Stage, number (%) | 0.80 | |||
| Extra-uterine | 84 (56.0%) | 58 (55.2%) | 26 (57.8%) | |
| Uterine-confined | 66 (44.0%) | 47 (44.8%) | 19 (42.2%) | |
| Molecular subtype, number (%) | 0.59 | |||
| POLE | 6 (4.0%) | 3 (2.9%) | 3 (6.7%) | |
| MMR-D | 44 (29.3%) | 33 (31.4%) | 11 (24.4%) | |
| CN-low-like (endometrioid-like) | 28 (18.7%) | 20 (19.0%) | 8 (17.8%) | |
| CN-high-like (serous-like) | 72 (48.0%) | 49 (46.7%) | 23 (51.1%) | |
| Median TMB, mut/Mb (IQR) | 6.7 (3.6, 24.4) | 6.7 (3.9, 25.7) | 6.9 (3.5, 15.8) | 0.40 |
IQR interquartile range, FIGO the International Federation of Gynecology and Obstetrics, POLE polymerase epsilon, MMR-D DNA mismatch repair-deficient, CN copy number, TMB tumor mutational burden, mut/Mb mutations per megabase.
*Categorical variables were compared using Fisher exact test; continuous variables were compared with Mann–Whitney U-test.